Certain genomic and molecular alterations, such as BRCA1/2-mutation (also known as BRCA1/2-mut) or other homologous recombination deficiency (HRD) are helpful in predicting the effectiveness of targeted therapy with poly(ADP-ribose)polymerase inhibitors (PARPis) in high-grade tumors [4]. This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.